Therapy Areas: Inflammatory Diseases
Therapeutic Solutions International Touts Positive Clinical Data on QuadraMune Reduction of SARS-CoV-2 Spike Protein Induced Inflammation
4 January 2022 - - US-based Therapeutic Solutions International has posted positive results of a pilot clinical trial in 20 subjects, the company said.

In the study, ten subjects received placebo and ten received twice daily doses of QuadraMune for seven days.

Blood monocytes were extracted and treated with SARS-CoV-2 spike protein in vitro for three time points.

A significantly decreased production of the inflammatory cytokine interleukin-6 was reported at all three timepoints.

Last week Therapeutic Solutions International received a notice of allowance granting a patent on the immune modulatory and COVID-19 inhibiting properties of QuadraMune.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases.
Login
Username:

Password: